DI-87

A late-stage ALS patient treated with Trethera's investigational drug TRE-515 under FDA's Expanded Access program showed disease stabilization over three months, with improvements in vital capacity and functional rating scales.

The global uveitis treatment market reached approximately $1.47 billion in 2022 across seven major markets and is projected to grow significantly through 2034, driven by emerging therapies and expanded treatment indications.